Search

Additional file 1 : Supplemental Table 1 Association of urine markers with 24 urine oxalate excretion (Uox), CaOx supersaturation (CaOx SS), proximal tubular oxalate concentration (PTOx), urine calcium/Cr, and urine citrate/Cr, among n = 30 PH patients, after removing those with urine laboratory values obtained more than 1 week away from the corresponding urine biobank specimen. P-values in bold denote significance at the 0.05 level. Models were fit using the GEE procedure with the normal distribution, identity link and exchangeable correlation specifications, unless noted otherwise. Models were adjusted for age, sex and eGFR. @ Only the urine concentrations unadjusted for creatinine were used since these variables are also adjusted for creatinine. ‡Log transformations were taken for all urine biomarkers as well as Uox, PTOx, Calcium/Cr and Citrate/Cr. Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL: ng/ml and ng/g Cr; 8 IP: pg/ml and ng/g Cr; MCP1: pg/ml and pg/g Cr; L-FABP: ng/ml and μg/g Cr; OPN: ng/ml and μg/g Cr; H-FABP: pg/ml and ng/g Cr.

Additional file 2 : Supplemental Table 2. Association of urine markers with eGFR among n = 30 PH patients, after removing those with serum creatinine values obtained more than 1 week away from the corresponding urine biobank specimen. P-values in bold denote significance at the 0.05 level. Models were fit using the GEE procedure with the normal distribution, identity link and exchangeable correlation specifications, unless noted otherwise. Models were adjusted for age and sex. ‡Log transformations were taken for all urine biomarkers as well as Uox, PTOx, Calcium/Cr and Citrate/Cr Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL: ng/ml and ng/g Cr; 8 IP: pg/ml and ng/g Cr; MCP1: pg/ml and pg/g Cr; L-FABP: ng/ml and μg/g Cr; OPN: ng/ml and μg/g Cr; H-FABP: pg/ml and ng/g Cr.

BackgroundUterine fibroids are a common problem for reproductive-aged women, yet little comparative effectiveness research is available to guide treatment choice. Uterine artery embolization and magnetic resonance imaging-guided focused ultrasound surgery are minimally invasive therapies approved by the US Food and Drug Administration for treating symptomatic uterine fibroids. The Fibroid Interventions: Reducing Symptoms Today and Tomorrow study is the first randomized controlled trial to compare these 2 fibroid treatments.ObjectiveThe objective of the study was to summarize treatment parameters and compare recovery trajectory and adverse events in the first 6 weeks after treatment.Study designPremenopausal women with symptomatic uterine fibroids seen at 3 US academic medical centers were enrolled in the randomized controlled trial (n= 57). Women meeting identical criteria who declined randomization but agreed to study participation were enrolled in a nonrandomized parallel cohort (n= 34). The 2 treatment groups were analyzed by using a comprehensive cohort design. All women undergoing focused ultrasound and uterine artery embolization received the same postprocedure prescriptions, instructions, and symptom diaries for comparison of recovery in the first 6 weeks. Return to work and normal activities, medication use, symptoms, and adverseevents were captured with postprocedure diaries. Data were analyzed using the Wilcoxon rank sum test or χ2 test. Multivariable regression was used to adjust for baseline pain levels and fibroid load when comparing opioid medication, adverse events, and recovery time between treatment groups because these factors varied at baseline between groups and could affect outcomes. Adverse events were also collected.ResultsOf 83 women in the comprehensive cohort design who underwent treatment, 75 completed postprocedure diaries. Focused ultrasound surgery was a longer procedure than embolization (mean [SD], 405 [146] vs 139 [44] min; P